HomeClinical TopicsFDA approves new drug for cystic fibrosis

FDA approves new drug for cystic fibrosis

On July 2, the U.S. Food and Drug Administration (FDA) approved Orkambi (lumacaftor 200 mg/ivacaftor 125 mg) for the treatment of cystic fibrosis (CF) in patients 12 years and older who have the F508del mutation. Having two copies of this mutation is the leading cause of CF. Read more.


Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Women suffering from a migraine

Quiz: Migraines and Hormones

Women are 2 to 3 times more likely than men to have migraines.  Decades ago, these were attributed to women’s inability to cope with...